Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinicius A Schoeps

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis and Related Disorders|December 9, 2022
Stroke Outcomes and Hyperacute Treatment Utilization in Multiple SclerosisVinicius A Schoeps, Emmanuelle Waubant, Nishita Singh
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 19, 2025
Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibilityVinicius A Schoeps, Jessica B Smith, Annette Langer-Gould
Multiple Sclerosis and Related Disorders|December 17, 2023
Smoking and multiple sclerosis risk in black people: A nested case-control studyVinicius A Schoeps, Marianna Cortese, Kassandra L Munger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 10, 2026
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort studyHui Chen, Marianna Cortese, Mario H Flores-Torres, et al.
Contemporary Clinical Trials|October 1, 2022
N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trialVinicius A Schoeps, Jennifer S Graves, William A Stern, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 11, 2026
High-dose <i>N</i>-acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trialVinicius A Schoeps, Raviola Murataj, Akash Virupakshaiah, et al.
Brain and Behavior|May 14, 2026
The Effect of Ocrelizumab on Anti-JC Virus Antibody IndexAkash Virupakshaiah, Alexander J Gill, Vinicius A Schoeps, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2026
Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosisFatemeh Siavoshi, Rezvan Noroozi, Gina Chang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 28, 2023
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated diseaseSimone Sacco, Akash Virupakshaiah, Nico Papinutto, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Accelerated Metabolomic Aging and Its Association with Social Determinants of Health in Multiple SclerosisFatemeh Siavoshi, Rezvan Noroozi, Gina Chang, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|December 9, 2022
Stroke Outcomes and Hyperacute Treatment Utilization in Multiple SclerosisVinicius A Schoeps, Emmanuelle Waubant, Nishita Singh
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 19, 2025
Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibilityVinicius A Schoeps, Jessica B Smith, Annette Langer-Gould
Multiple Sclerosis and Related Disorders|December 17, 2023
Smoking and multiple sclerosis risk in black people: A nested case-control studyVinicius A Schoeps, Marianna Cortese, Kassandra L Munger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 10, 2026
Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort studyHui Chen, Marianna Cortese, Mario H Flores-Torres, et al.
Contemporary Clinical Trials|October 1, 2022
N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trialVinicius A Schoeps, Jennifer S Graves, William A Stern, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 11, 2026
High-dose <i>N</i>-acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trialVinicius A Schoeps, Raviola Murataj, Akash Virupakshaiah, et al.
Brain and Behavior|May 14, 2026
The Effect of Ocrelizumab on Anti-JC Virus Antibody IndexAkash Virupakshaiah, Alexander J Gill, Vinicius A Schoeps, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 20, 2026
Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosisFatemeh Siavoshi, Rezvan Noroozi, Gina Chang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 28, 2023
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated diseaseSimone Sacco, Akash Virupakshaiah, Nico Papinutto, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Accelerated Metabolomic Aging and Its Association with Social Determinants of Health in Multiple SclerosisFatemeh Siavoshi, Rezvan Noroozi, Gina Chang, et al.
Pageof 2